---
figid: PMC6134417__zgfazz-13-9-C10-1
figtitle: 抗表皮生长因子受体和抗血管内皮生长因子药物在非小细胞肺癌治疗中的作用
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC6134417
filename: zgfazz-13-9-C10-1.jpg
figlink: /pmc/articles/PMC6134417/figure/Figure1/
number: F1
caption: 'EGFR和VEGFR激活的下游信号转导和生物过程以及抑制这些信号通路组分的靶向治疗。肿瘤细胞中EGFR的激活会引起受体激酶区域内酪氨酸残基的磷酸化以及后续的Ras/Raf/MAPK或PI3K/Akt/mTOR通路的激活，这将导致血管生成、细胞增殖、生长、转移和粘附相关基因的核激活。其它生长因子受体通路（如IGF-1R）的激活亦可通过PI3K和其它下游组分而传递信号，进而导致基因转录。内皮细胞中VEGFR的激活亦可活化Ras/Raf/MAPK通路，并调节基因表达和细胞存活。有两种策略可抑制EGFR介导的信号：可与细胞内激酶区域结合的小分子TKI（如，厄洛替尼和吉非替尼）或可结合于细胞外并阻止配体结合的单克隆抗体，如西妥昔单抗。可与VEGF配体直接结合并阻止受体激活的抗VEGF抗体（如，贝伐珠单抗）或VEGFR的小分子TKI（如，舒尼替尼和索拉非尼）亦可同样抑制VEGF介导的下游信号。Signal
  transduction and biologic processes downstream of egfr and vegfr activation and
  targeted therapies that inhibit components of these signaling pathways. Activation
  of EGFR on tumor cells leads to phosphorylation of tyrosine residues in the kinase
  domain of the receptor and subsequent activation of the Ras/Raf/MAPK or the PI3K/Akt/mTOR
  pathways, resulting in nuclear activation of genes related to angiogenesis, cell
  proliferation, growth, metastasis, and adhesion. Activation of other growth factor
  receptor pathways (eg, IGF-1R) also signal via PI3K and other downstream components,
  resulting in gene transcription. Activation of VEGFR on endothelial cells also activates
  the Ras/Raf/MAPK pathway and regulates gene expression and survival. Two strategies
  are available to inhibit EGFR-mediated signaling: small-molecule TKIs (eg, erlotinib
  and gefitinib) that bind to the intracellular kinase domain or monoclonal antibodies
  such as cetuximab, which bind extracellularly and prevent ligand binding. VEGF-mediated
  downstream signaling can be similarly abrogated via anti-VEGF antibodies (eg, bevacizumab),
  which bind directly to the VEGF ligand and prevent receptor activation, or by small-molecule
  TKIs (eg, sunitinib and sorafenib) of the VEGFR.'
papertitle: 抗表皮生长因子受体和抗血管内皮生长因子药物在非小细胞肺癌治疗中的作用.
reftext: Corey LANGER, et al. Zhongguo Fei Ai Za Zhi. 2010 Sep 20;13(9):C10-C22.
year: '2010'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9313781
figid_alias: PMC6134417__F1
figtype: Figure
redirect_from: /figures/PMC6134417__F1
ndex: 73577675-df0a-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6134417__zgfazz-13-9-C10-1.html
  '@type': Dataset
  description: 'EGFR和VEGFR激活的下游信号转导和生物过程以及抑制这些信号通路组分的靶向治疗。肿瘤细胞中EGFR的激活会引起受体激酶区域内酪氨酸残基的磷酸化以及后续的Ras/Raf/MAPK或PI3K/Akt/mTOR通路的激活，这将导致血管生成、细胞增殖、生长、转移和粘附相关基因的核激活。其它生长因子受体通路（如IGF-1R）的激活亦可通过PI3K和其它下游组分而传递信号，进而导致基因转录。内皮细胞中VEGFR的激活亦可活化Ras/Raf/MAPK通路，并调节基因表达和细胞存活。有两种策略可抑制EGFR介导的信号：可与细胞内激酶区域结合的小分子TKI（如，厄洛替尼和吉非替尼）或可结合于细胞外并阻止配体结合的单克隆抗体，如西妥昔单抗。可与VEGF配体直接结合并阻止受体激活的抗VEGF抗体（如，贝伐珠单抗）或VEGFR的小分子TKI（如，舒尼替尼和索拉非尼）亦可同样抑制VEGF介导的下游信号。Signal
    transduction and biologic processes downstream of egfr and vegfr activation and
    targeted therapies that inhibit components of these signaling pathways. Activation
    of EGFR on tumor cells leads to phosphorylation of tyrosine residues in the kinase
    domain of the receptor and subsequent activation of the Ras/Raf/MAPK or the PI3K/Akt/mTOR
    pathways, resulting in nuclear activation of genes related to angiogenesis, cell
    proliferation, growth, metastasis, and adhesion. Activation of other growth factor
    receptor pathways (eg, IGF-1R) also signal via PI3K and other downstream components,
    resulting in gene transcription. Activation of VEGFR on endothelial cells also
    activates the Ras/Raf/MAPK pathway and regulates gene expression and survival.
    Two strategies are available to inhibit EGFR-mediated signaling: small-molecule
    TKIs (eg, erlotinib and gefitinib) that bind to the intracellular kinase domain
    or monoclonal antibodies such as cetuximab, which bind extracellularly and prevent
    ligand binding. VEGF-mediated downstream signaling can be similarly abrogated
    via anti-VEGF antibodies (eg, bevacizumab), which bind directly to the VEGF ligand
    and prevent receptor activation, or by small-molecule TKIs (eg, sunitinib and
    sorafenib) of the VEGFR.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
  - Egfr
  - ras
  - Ras64B
  - Ras85D
  - Raf
  - MKP-4
  - p38b
  - rl
  - Akt
  - Mtor
  - Tor
  - TRAP
  - ACP5
  - CD40LG
  - TRAF2
  - TRRAP
  - TDRD7
  - SCYL1
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - IGF1R
  - EGFR
  - KDR
  - FLT1
  - FLT4
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - Cancer
---
